TGF-β superfamily enhances the antigen-induced IFN-γ production by effector/memory CD8+T cells

International Journal of Molecular Medicine

Volumn 25, Issue 1, 2010, Pages 105-111

  Takai, Shinji ^a   Tokuda, Haruhiko ^b   Matsushima Nishiwaki, Rie ^a   Saio, Masanao ^a   Takami, Tsuyoshi ^a   Kozawa, Osamu ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Effector memory T cells; IFN ; TGF ; Tumor immunity

Indexed keywords

ACTIVIN A; BONE MORPHOGENETIC PROTEIN 4; GAMMA INTERFERON; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EFFECTOR CELL; MEMORY CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR BLOCKING;

ACTIVINS; ANIMALS; BONE MORPHOGENETIC PROTEIN 4; CD8-POSITIVE T-LYMPHOCYTES; CLONE CELLS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MICE; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SILVER; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 70549089795     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000319     Document Type: Article

References (29)

1. Gattinoni L, Powell DJ Jr, Rosenberg SA and Restifo NP: Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6: 383-393, 2006.
2. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H and Ohtani H: Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 61: 5132-5136, 2001.
3. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58: 3491-3494, 1998.
4. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC and Coukos G: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213, 2003.
5. Menard S, Tomasic G, Casalini P, Balsari A, Pilotti S, Cascinelli N, Salvadori B, Colnaghi MI and Rilke F: Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res 3: 817-819, 1997.
6. Rosenberg SA, Yang JC and Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915, 2004.
7. Frey AB and Monu N: Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response. J Leukoc Biol 79: 652-662, 2006.
8. Gorelik L and Flavell RA: Transforming growth factor beta in T cell biology. Nat Rev Immunol 2: 46-53, 2002.
9. Wojtowicz-Praga S: Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs 21: 21-32, 2003.
10. Li H, Han Y, Guo Q, Zhang M and Cao X: Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J Immunol 182: 240-249, 2009.
11. Terabe M, Khanna C, Bose S, Melchionda F, Mendoza A, Mackall CL, Helman LJ and Berzofsky JA: CD1d-restricted natural killer T cells can down-regulate tumor immuno-surveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta. Cancer Res 66: 3869-3875, 2006.
12. Thomas DA and Massague J: TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8: 369-380, 2005.
13. + T cell survival, division, and IL-2 production: a role for T cell intrinsic Smad3. J Immunol 174: 2071-2083, 2005.
14. Joncker NT, Marloie MA, Chernysheva A, Lonchay C, Cuff S, Klijanienko J, Sigal-Zafrani B, Vincent-Salomon A, Sastre X and Lantz O: Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumors. Int J Cancer 118: 1205-1214, 2006.
15. Bettelli E, Carrier Y, Gao W, Korn T, Storm TB, Oukka M, Weiner HL and Kuchroo VK: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235-238, 2006.
16. Ando K, Moriyama T, Guidotti LG, Wirth S, Schreiber RD, Schlicht HJ, Huang SN and Chisari FV: Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 178: 1541-1554, 1993.
17. Takai S, Kimura K, Nagaki M, Satake S, Kakimi K and Moriwaki H: Blockade of neutrophil elastase attenuates severe liver injury in hepatitis B transgenic mice. J Virol 79: 15142-15150, 2005.
18. Miyazono K, ten Dijke P and Heldin CH: TGF-beta signaling by Smad proteins. Adv Immunol 75: 115-157, 2005.
19. Shi Y and Massague J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685-700, 2003.
20. McHeyzer-Williams LJ and McHeyzer-Willams MG: Antigen-specific memory B cell development. Annu Rev Immunol 23: 487-513, 2005.
21. + T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8: 379-385, 2002.
22. Tomiyama H, Matsuda T and Takigichi M: Differentiation of human CD8(+) T cells from a memory to memory/effector phenotype. J Immunol 168: 5538-5550, 2002.
23. De Rosa SC, Herzenberg LA and Roederer M: 11-color, 13-parameter flow cytometry: identification of human naïve T cells by phenotype, function and T-cell receptor diversity. Nat Med 7: 245-249, 2001.
24. + T-cell differentiation in response to viruses. Nat Rev Immunol 3: 931-938, 2003.
25. Sacre K, Carcelain G, Cassoux N, Fillet AM, Costagliola D, Vittecoq D, Salmon D, et al: Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med 201: 1999-2010, 2005.
26. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D and Levitsky H: The central role of CD41 T cells in the anti-tumor immune response. J Exp Med 188: 2357-2368, 1998.
27. Fallarino F and Gajewski TF: Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1. J Immunol 163: 4109-4113, 1999.
28. Restifo NP, Esquivel F, Asher AL, Stotter H, Barth RJ, Bennink JR, Mule JJ, et al: Defective presentation of endogenous antigens by a murine sarcoma: implications for the failure of an anti-tumor immune response. J Immunol 147: 1453-1459, 1991.
29. Russell JH and Ley TJ: Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 20: 323-370, 2002.